Company Encyclopedia
View More
name
MAIA Biotech
MAIA.US
MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
1.935 T
MAIA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Short Interest Up 144.9% in December

    MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) experienced a 144.9% increase in short interest in December, totaling 1,685,137 shares. Currently, 6.7% of the company's shares are sold short, with a short-interest ratio of 1.1 days. Insider buying was noted, with directors acquiring significant shares. The stock rose 6.1% to $1.57, with a market cap of $58.14 million. MAIA Biotechnology is a clinical-stage biopharmaceutical company focusing on monoclonal antibodies and radiotherapeutics.

    Market Beat·
    US
    MAIA
    +6.08%
    Market Beat·
    US
    MAIA
    +6.08%

    MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings | MAIA Stock News

    MAIA Biotechnology announced that board members, including Adelina Louie and Stan V. Smith, purchased shares and warrants in a private placement, reflecting confidence in ateganosine's potential. The offering raised $1.51 million, with directors holding 13.43% of MAIA. Ateganosine, a telomere-targeting agent for NSCLC, has FDA Fast Track designation. The Phase 3 trial is underway, aiming for regulatory approval. MAIA focuses on developing first-in-class cancer treatments.

    StockTitan·
    US
    MAIA
    +6.08%
    StockTitan·
    US
    MAIA
    +6.08%

    MAIA Biotechnology Announces $2.25M Private Placement Deal

    MAIA Biotechnology, Inc. announced a $2.25 million private placement deal with accredited investors and directors, aligning leadership interests with shareholders. The funds will support Phase II clinical trials of the THIO-101 program and general working capital. The transaction is expected to close on December 18, 2025. Despite weak financial performance due to its development-stage status, recent positive trial results and technical indicators show short-term upward momentum for MAIA stock.

    Tip Ranks·
    US
    MAIA
    +6.08%
    Tip Ranks·
    US
    MAIA
    +6.08%

    MAIA Biotechnology, Inc. (MAIA) Gets a Buy from Noble Financial

    Noble Financial analyst Robert LeBoyer reiterated a Buy rating for MAIA Biotechnology, Inc., setting a price target of $14.00. The stock closed at $1.23, with an analyst consensus of Moderate Buy. LeBoyer, who covers the Healthcare sector, has an average return of -11.7% and a 27.76% success rate.

    Tip Ranks·
    US
    MAIA
    +6.08%
    Tip Ranks·
    US
    MAIA
    +6.08%

    MAIA Biotechnology announces $1.51M private placement

    MAIA Biotechnology announced a $1.51M private placement involving 1.23M shares at $1.224 each, with warrants to purchase additional shares at $1.36. The placement is expected to close by December 18, 2025. Proceeds will fund a Phase II trial and working capital. Shares fell 8.89%.

    MSN·
    US
    MAIA
    +6.08%
    MSN·
    US
    MAIA
    +6.08%
    © 2025 Longbridge｜Disclaimer